1. Home
  2. BLTE vs SXT Comparison

BLTE vs SXT Comparison

Compare BLTE & SXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$161.06

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Logo Sensient Technologies Corporation

SXT

Sensient Technologies Corporation

N/A

Current Price

$134.56

Market Cap

5.7B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
BLTE
SXT
Founded
2018
1882
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
5.7B
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
BLTE
SXT
Price
$161.06
$134.56
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
$198.00
$121.00
AVG Volume (30 Days)
153.2K
445.2K
Earning Date
05-08-2026
04-24-2026
Dividend Yield
N/A
1.36%
EPS Growth
N/A
7.48
EPS
N/A
2.24
Revenue
N/A
$1,396,499,000.00
Revenue This Year
N/A
$8.99
Revenue Next Year
$492.11
$9.45
P/E Ratio
N/A
$59.19
Revenue Growth
N/A
N/A
52 Week Low
$62.18
$82.60
52 Week High
$200.00
$136.58

Technical Indicators

Market Signals
Indicator
BLTE
SXT
Relative Strength Index (RSI) 51.24 64.77
Support Level $158.32 $109.48
Resistance Level $172.02 N/A
Average True Range (ATR) 6.82 3.35
MACD -0.74 0.18
Stochastic Oscillator 27.85 81.06

Price Performance

Historical Comparison
BLTE
SXT

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

About SXT Sensient Technologies Corporation

Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are: Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.

Share on Social Networks: